Mithra announces new agreement with GSP for development of an additional injectable

/in , /by

Agreement with Generic Specialty Pharma (GSP), a leading generics player, for development and supply of a fifth hormonal injectable. Expansion of Mithra CDMO’s portfolio of activities, confirming its profile as a unique industrial partner in the development and production of a complete range of specialized medical products and devices. Liege, Belgium, 18 April 2019 – […]

Read more →

Mithra Releases 2018 Annual Report and Invitation to its General Shareholders’ Meeting

/in /by

Liege, Belgium, 8 April 2019 – 7:30  CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health today announces the publication of its 2018 Annual Report and the invitation to its Ordinary and Extraordinary General Shareholders’ meeting. Annual Report The Annual Report which outlines Mithra’s achievements in 2018 includes the following information: Overview of […]

Read more →

Mithra wins essenscia Innovation Award 2019 for its new generation contraceptive pill, Estelle®

/in , /by

Mithra wins the Essenscia Innovation Award, the most prestigious prize for industrial innovation in Belgium Jury of experts recognize the major breakthrough and worldwide potential of this new generation contraceptive pill Capping more than 20 years of research and development, this award was presented by her Royal Highness, the Princess Astrid, during a ceremony at […]

Read more →

Mithra receives Orphan Drug Designation from FDA for E4 in neonatal encephalopathy treatment

/in , /by

The US Food and Drug Administration granted E4 an ODD for the treatment of life-threatening hypoxic ischemic encephalopathy (HIE) This new designation expands E4’s broad potential in therapeutic areas beyond the leading indications in women’s health Mithra continues its preclinical studies in HIE, a severe pediatric syndrome that affects 30,000 newborns each year in Europe […]

Read more →

Mithra Demonstrates Further Estetrol’s Unique Profile at the Annual Meeting of the Endocrine Society

/in , /by

Liege, Belgium, 25 March 2019 – 7 :30  CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health has presented the results of a new study on Estetrol (E4) at the 101st Annual Meeting of the Endocrine Society (ENDO 2019) held from March 23 to 26 in New Orleans (U.S.)  

Read more →

Mithra Signs License and Supply Agreement for Commercialization of Tibelia® in Chile

/in , /by

Mithra strengthens its presence in the fast-growing Chilean market with an agreement for commercialization of the hormone treatment Tibelia® with Saval Pharmaceuticals Tibelia® is currently marketed in about ten countries through existing license and supply agreements and just adds an additional market in Spain after winning a public tender Liege, Belgium, 05 March 2019 – […]

Read more →

Mithra Reports 2018 Annual Results

/in , /by

Strong revenue growth (+42%) with significantly improved EBITDA (record level of EUR 38.3 M vs. EUR -18.4 M in 2017) and cash position (EUR 119 M vs. EUR 36.2 M in 2017) thanks to increased business development activities Strengthening Mithra’s international deployment through key partnerships with women’s health leaders Clinical milestones successfully achieved for highly promising portfolio […]

Read more →

Mithra Signs Partnership Agreement With Itrom for Commercialization of Estelle® in the Middle East

/in , /by

Mithra strengthens its presence in the Middle East with a third partnership with UAE-based ITROM Pharmaceutical Group for the combined oral contraceptive Estelle® Following the publication of the positive top-line results of the Estelle® Phase III study, Mithra is intensifying its business development strategy of its potential contraceptive blockbuster in key international markets Agreement follows […]

Read more →

Information on the Total Number of Voting Rights (Denominator)

/in , /by

Liege, Belgium, 25 February 2019 – 17:45 CET – In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Mithra Pharmaceuticals SA announces the following information, following the issuance of 24,750 new shares on 30 January 2019 for an amount of EUR 84 690 as the result […]

Read more →

Mithra Announces New Polymer Technology Development for a Leading Veterinarian Company

/in , /by

First veterinary R&D project concluded with one of the world’s largest animal health players, CEVA Development of an innovative hormonal device for the bovine fertility market Expansion of Mithra CDMO polymer technology expertise attracts new development partners Liege, Belgium, 20 February 2019 – 7:30  CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s […]

Read more →